Regeneron (REGN) stock trades up, here is why

Regeneron (REGN) shares rose 11.5% after reporting Q3 2026 revenue of $5.1B, up 36%, and EPS of $20.07, up 70%. The company cited record sales for key drugs and expanded its alliance with Sanofi. REGN also announced pipeline milestones and updated trial data for Libtayo. The stock has gained 17.3% YTD, reaching a 52-week high of $910.25.

Original reporting
Published Oct 30, 2026, 5:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 6:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Regeneron (REGN) stock trades up, here is why — source image
Decision brief

The 30-second read

$REGNBullishHigh
01

Why it matters

The earnings beat and pipeline milestones are likely to drive further buying interest, especially given the rare large‑move for the stock.

02

Market read

Regeneron's strong earnings and partnership news provide a clear catalyst for short‑term upside.

03

What to watch

Potential headwinds from competition in immunology and the need for FDA approval of cemdisiran.

Relevance 9/10Novelty 9/10Timing: afternoon session today

Background

Regeneron announced record sales for Dupixent, EYLEA HD, and Libtayo, and expanded its alliance with Sanofi, alongside a Phase 3 trial showing a 37% mortality reduction for Libtayo.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Regeneron reported Q3 2026 revenue up 36% and EPS up 70%, driving an 11.5% share jump in the afternoon session.

Expected impact

upward pressure as the market prices in the revenue and earnings beat.

Evidence & confidence

First‑report earnings with double‑digit price move and significant revenue growth for a large‑cap biotech.

Market effects

Boosts sentiment for the biotech sector as Regeneron's results exceed expectations.

Positive for US biotech stocks and related healthcare indices.

May influence global biotech investors tracking US earnings trends.

Counterpoint

Some investors may worry about execution risk of the expanded Sanofi partnership and upcoming regulatory decision.

Key entities

  • Regeneron Pharmaceuticals

    Biotech firm reporting Q3 2026 results.

  • Sanofi

    Pharmaceutical partner in expanded immunology alliance.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.